DE69831951T2 - Pseudomonas exotoxin a-ähnliche chimäre immunogene - Google Patents

Pseudomonas exotoxin a-ähnliche chimäre immunogene Download PDF

Info

Publication number
DE69831951T2
DE69831951T2 DE69831951T DE69831951T DE69831951T2 DE 69831951 T2 DE69831951 T2 DE 69831951T2 DE 69831951 T DE69831951 T DE 69831951T DE 69831951 T DE69831951 T DE 69831951T DE 69831951 T2 DE69831951 T2 DE 69831951T2
Authority
DE
Germany
Prior art keywords
domain
sequence
immunogen
epitope
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69831951T
Other languages
German (de)
English (en)
Other versions
DE69831951D1 (de
Inventor
J. David FITZGERALD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69831951D1 publication Critical patent/DE69831951D1/de
Publication of DE69831951T2 publication Critical patent/DE69831951T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69831951T 1997-07-11 1998-07-10 Pseudomonas exotoxin a-ähnliche chimäre immunogene Expired - Lifetime DE69831951T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5237597P 1997-07-11 1997-07-11
US52375P 1997-07-11
PCT/US1998/014341 WO1999002713A1 (en) 1997-07-11 1998-07-10 Pseudomonas exotoxin a-like chimeric immunogens

Publications (2)

Publication Number Publication Date
DE69831951D1 DE69831951D1 (de) 2006-03-02
DE69831951T2 true DE69831951T2 (de) 2006-07-27

Family

ID=21977213

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69831951T Expired - Lifetime DE69831951T2 (de) 1997-07-11 1998-07-10 Pseudomonas exotoxin a-ähnliche chimäre immunogene

Country Status (10)

Country Link
US (1) US8092809B2 (enExample)
EP (1) EP1000163B1 (enExample)
JP (2) JP2001510683A (enExample)
AT (1) ATE307208T1 (enExample)
AU (1) AU731703B2 (enExample)
CA (1) CA2295971C (enExample)
DE (1) DE69831951T2 (enExample)
DK (1) DK1000163T3 (enExample)
ES (1) ES2249838T3 (enExample)
WO (1) WO1999002713A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078988A1 (en) * 1999-08-27 2001-02-28 Academia Sinica Pseudomonas fusion protein vaccines
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
ATE444081T1 (de) * 1999-10-22 2009-10-15 Us Gov Health & Human Serv Proteine-abgabe durch polare epithelzellen schichte
TWI293957B (en) * 2004-07-21 2008-03-01 Healthbanks Biotech Co Ltd A superantigen fusion protein and the use thereof
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
CN101969975B (zh) * 2008-01-31 2013-06-05 生控基因疫苗股份有限公司 作为疫苗的hiv嵌合融合蛋白
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
BR112015013183A2 (pt) * 2012-12-05 2017-09-26 Thevax Genetics Vaccine Co Ltd proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
WO2014172309A2 (en) 2013-04-18 2014-10-23 The United States Of America As Represented By The Secretary Of The Army, On Behalf Of The United Therapeutic compositions for neutralizing type i interferons, and methods of use
DK3302543T3 (da) * 2015-06-01 2020-05-18 Reber Genetics Co Ltd Vaccinesammensætninger mod porcint reproduktions- og respirationssyndrom og porcint circovirus-associerede sygdomme
EP4316586A3 (en) 2018-03-08 2024-05-08 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
JP7487193B2 (ja) 2018-11-07 2024-05-20 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA1289880C (en) 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5206353A (en) 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
CA1340530C (en) 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU657087B2 (en) * 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
AU646673B2 (en) 1990-05-11 1994-03-03 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5190873A (en) 1991-06-21 1993-03-02 California Institute Of Biological Research Hybrid tryptophan aporepressor containing ligand binding sites
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
ATE314475T1 (de) 1992-06-18 2006-01-15 Us Gov Health & Human Serv Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
ATE204300T1 (de) 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
EP0789776B1 (en) 1994-11-01 2001-06-13 Winfried Wels Nucleic acid transfer system
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5980895A (en) 1995-10-13 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
CA2241604C (en) 1996-01-05 2010-03-30 Ira Pastan Mesothelium antigen and methods and kits for targeting it
AU716564B2 (en) * 1996-11-06 2000-03-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Protease-activatable pseudomonas exotoxin A-like proproteins
WO1998042876A1 (en) 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6140066A (en) 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
EP1224290B1 (en) 1999-10-22 2006-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Disulfide conjugated cell toxins and methods of making and using them
ATE444081T1 (de) * 1999-10-22 2009-10-15 Us Gov Health & Human Serv Proteine-abgabe durch polare epithelzellen schichte
US6783761B2 (en) 2000-05-05 2004-08-31 Aphton Corporation Chimeric peptide immunogens
WO2002060935A2 (en) * 2000-12-21 2002-08-08 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
CA2501235A1 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
JP2006516091A (ja) * 2002-10-07 2006-06-22 アンティジェニクス インコーポレーテッド 熱ショックタンパク質結合性のｃｄ９１断片およびその使用
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
AU2005294436A1 (en) * 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
DK2308514T3 (da) * 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
WO2008124010A1 (en) * 2007-04-06 2008-10-16 The Trustees Of The University Of Pennsylvania Surfactant protein d is a biomarker for steroid responsiveness in asthma and chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
JP2009079068A (ja) 2009-04-16
ATE307208T1 (de) 2005-11-15
AU8481398A (en) 1999-02-08
US20090269368A1 (en) 2009-10-29
DK1000163T3 (da) 2006-02-06
EP1000163B1 (en) 2005-10-19
CA2295971A1 (en) 1999-01-21
US8092809B2 (en) 2012-01-10
JP2001510683A (ja) 2001-08-07
DE69831951D1 (de) 2006-03-02
AU731703B2 (en) 2001-04-05
CA2295971C (en) 2011-02-08
WO1999002713A1 (en) 1999-01-21
ES2249838T3 (es) 2006-04-01
EP1000163A1 (en) 2000-05-17

Similar Documents

Publication Publication Date Title
DE69738329T2 (de) Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins
US8092809B2 (en) Pseudomonas exotoxin A-like chimeric immunogens
US20090081235A1 (en) Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7314632B1 (en) Pseudomonas exotoxin A-like chimeric immunogens
DE60038620T2 (de) Dna immunisierung gegen chlamydia infektion
DE3881204T2 (de) Moleküle mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum-produzierten proteins in hepatozyten und zusammensetzungen davon.
DE69229107T2 (de) Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen
DE69535360T2 (de) Synthetische peptide und impfstoffe welche diese beinhalten
DE69836024T2 (de) Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga-vermittelten immunantwort
DE69836333T2 (de) Neisseria lactoferrin-bindendes protein
DE69931518T2 (de) Chimäres Gen, das für die antigenischen Determinaten von vier Proteinen aus L. Infantum kodiert
US6103239A (en) Modified HGP-30 heteroconjugates, compositions and methods of use
US6111068A (en) HIV-1 p-17 peptide fragments, compositions containing and methods for producing and using same
US20090098144A1 (en) Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies
EP4598943A2 (en) Novel chimeric multi-protein based recombinant vaccine antigens for prevention of lyme disease in animals and humans
DE69116155T2 (de) Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE60037413T2 (de) Rekombinante adhesin-proteine aus haemophilus influenzae
US6258945B1 (en) HIV-1P-17 peptide fragments, compositions containing and methods for producing and using same
EP1696033A2 (en) Pseudomonas exotoxin A-like chimeric immunogens
EP1660523A2 (de) Induktion antiviraler neutralisierender antikörper beim menschen und beim tier
DE10339966A1 (de) Induktion antiviraler neutralisierender Antikörper beim Menschen und beim Tier
KR19980702834A (ko) 레트로바이러스 조절 단백질로부터 유래된 비독성 면역원, 항체, 그들의 제조 방법, 및 그들을 함유한 제약 조성물
DE60127401T2 (de) Milchvieh immunisierung mit mig protein
CA2253834A1 (en) B. burgdorferi polypeptides expressed in vivo
EP1337647A2 (de) Das helicobacter cystein rich protein a (hcpa) und seine anwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition